Risk-sharing agreements (RSAs) have been introduced to allocate risk between payers and pharmaceutical companies, often taking the form of outcome-based or financial-based models.
This study seeks to explore the perspectives of key stakeholders within Singapore’s healthcare system regarding value-based payment mechanisms for high-cost technologies. Specifically, the objectives are to: (i) identify the perceptions, barriers, and enablers related to the implementation of RSAs; (ii) describe both feasible and ideal schemes for their implementation, and determine priority areas for their application; and (iii) gather insights on strategies for capacity building.
The findings indicate that while value-based payment mechanisms have the potential to reduce uncertainty and improve access to healthcare technologies, addressing the barriers to effective risk-sharing agreements is crucial for their success.